Financial Times - Aug 8
Aug 8 (Reuters) -The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
Headlines
- NHS in England to roll out 1.7 mln pound Crispr gene editing drug
- Ministry of Defence asks suppliers to identify budget cuts
- H2O Asset Management to pay investors 250 mln euros after FCA finds 'serious breaches'
- UK signals move to curb overseas hiring for tech and engineering jobs
Overview
- Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics CRSP.BN to treat rare blood disorder beta thalassemia.
- The British Ministry of Defence has asked all major industry suppliers to identify opportunities for immediate budget cuts.
- Asset manager H2O has voluntarily offered to pay 250 million euros ($273.30 million) to investors trapped in funds since 2020 and will shut its UK operation.
- The UK government has signalled it wants to curb overseas hiring by engineering and technology companies, after it asked independent advisers to review the reliance of the sector on skilled worker visas.
($1 = 0.9147 euros)
(Compiled by Bengaluru newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
